FEBS Letters · 1996 · 376 citations · 39 references
Life SciencesBiochemistryMolecular BiologyEnzymologyGlycobiologyRheumatologyCartilage BiologyCartilage BreakdownCartilage MetabolismExtracellular MatrixJoint DiseaseAggrecan BiologyArticular Cartilage ProteoglycansCartilage Breakdown PathophysiologyCartilage Degradation MechanismsMatrix MetalloproteinasesProtease Cleavage SitesProteoglycan Biology
Aggrecan degradation in arthritis involves unidentified aggrecanases and matrix metalloproteinases, with cleavage sites identified in the interglobular domain, and chondrocyte stimulation with retinoic acid induces expression of collagenase‑3 (MMP‑13). The study examined the specificity of MMP‑13 for aggrecan. MMP‑13 cleaves aggrecan in the IGD at the same site as other MMPs and at a novel site (VKP384‑VFE) not seen with other proteinases.
Degradation of the large cartilage proteoglycan aggrecan in arthritis involves an unidentified enzyme aggrecanase, and at least one of the matrix metalloproteinases. Proteinase-sensitive cleavage sites in the aggrecan interglobular domain (IGD) have been identified for many of the humman MMPs, as well as for aggrecanase and other proteinases. The major MMP expressed by chondrocytes stimulated with retinoic acid to degrade their matrix is collagenase-3 or MMP-13. Because of its potential role in aggrecan degradation we examined the specificity of MMP-13 for an aggrecan substrate. The results show that MMP-13 cleaves aggrecan in the IGD at the same site (..PEN314-FFG..) identified for other members of the MMP family, and also at a novel site ..VKP384-VFE.. not previously observed for other proteinases.
39
Stefan Lohmander, Peter J. Neame, John D. Sandy · Arthritis & Rheumatism · 1993 · 437 citations
Medicine, Biochemistry, Immunology +17
John D. Sandy, Carl R. Flannery, Peter J. Neame et al. · Journal of Clinical Investigation · 1992 · 416 citations · Full text